AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)

The title of this study is"The Impact of Multimodal Digital Fusion AI-Assisted Decision Support System-Based Comprehensive Management on Clinical Outcomes in County-Level Patients with Comorbid Cancer: A prospective non-randomized controlled interventional study", to evaluate the impact of full-course management based on a multimodal digital fusion AI-assisted decision support system on the clinical outcomes of county-level oncologic comorbid patients through a prospective non-randomized controlled interventional study. The study plans to enroll 5,000 patients with pathologically confirmed malignancies and at least one comorbid condition (diabetes, hypertension, etc.) , in the first stage, the epidemiological characteristics of co-morbidity and its impact on prognosis, treatment response and quality of life were analyzed In the second phase, patients with comorbid pulmonary malignancies were selected to compare the clinical effects of the voluntary whole-process management group (including personalized intervention such as nutritional screening and dynamic monitoring) and the conventional treatment group, the third stage integrates multi-center Electronic Medical Records, genomic data, wearable device monitoring and other multi-modal data to construct an AI decision-making system, developing risk stratification, personalized treatment recommendation, and dynamic prognostic prediction models, finally, the differences in core indicators such as survival rate (PFS, OS) , complication control and medical resource efficiency between AI-assisted management and traditional mode were compared. This study realizes the integrated intervention of in-hospital and out-of-hospital through digital whole-process management, which is expected to provide an AI-driven precise decision support paradigm for primary medical institutions and improve the efficiency of comprehensive management of tumor comorbidity.

Inclusion criteria

• Patients with a definite diagnosis of malignancy by histopathology and/or cytology;
• Age ≥18 years;
• There is no gender limit
• Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ;
• Conscious and able to answer questions and use electronic devices autonomously;
• Patients were able to understand the study and voluntarily sign an informed consent form;

Exclusion criteria

• Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme;
• With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness;
• Women during pregnancy or lactation；
• Have participated in other interventional studies in the past 1 month or are currently participating;
• Patients with ECOG ≥ 3 that do not respond to treatment;
• Patients with an expected survival of < 3 months that do not respond to treatment;
• Cases deemed unsuitable for enrollment by the investigator.